Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Unknown × oregovomab × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Terminated 2 Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 37 Gemcitabine 30 Paclitaxel 28 Cisplatin 28 Capecitabine 27 Carboplatin 26 camrelizumab 24 Nivolumab 23 apatinib 22 Oxaliplatin 21 fludarabine 20 Radiotherapy 20 toripalimab 18 Drug Therapy 18 pembrolizumab 17 Immunotherapy, Adoptive 17 Docetaxel 17 Dexamethasone 15 Bevacizumab 15 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14 Temozolomide 13 Rituximab 13 Injections 13 tislelizumab 12 Cetuximab 12 Irinotecan 11 anlotinib 10 Fluorouracil 10 Cytarabine 10 130-nm albumin-bound paclitaxel 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04620954 2021-12-01

ORION-02

National Cancer Centre, Singapore

Phase 1/2 Unknown

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡